ArQule Shares Outstanding 2006-2018 | ARQL

ArQule shares outstanding from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ArQule Annual Shares Outstanding
(Millions of Shares)
2017 75
2016 70
2015 63
2014 63
2013 62
2012 60
2011 53
2010 45
2009 44
2008 44
2007 40
2006 36
2005 35
ArQule Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 107
Q2 2018 101
Q1 2018 87
Q4 2017 75
Q3 2017 72
Q2 2017 71
Q1 2017 71
Q4 2016 70
Q3 2016 71
Q2 2016 71
Q1 2016 65
Q4 2015 63
Q3 2015 63
Q2 2015 63
Q1 2015 63
Q4 2014 63
Q3 2014 63
Q2 2014 63
Q1 2014 63
Q4 2013 62
Q3 2013 63
Q2 2013 62
Q1 2013 62
Q4 2012 60
Q3 2012 62
Q2 2012 61
Q1 2012 54
Q4 2011 53
Q3 2011 54
Q2 2011 53
Q1 2011 51
Q4 2010 45
Q3 2010 45
Q2 2010 45
Q1 2010 44
Q4 2009 44
Q3 2009 44
Q2 2009 44
Q1 2009 44
Q4 2008 44
Q3 2008 44
Q2 2008 44
Q1 2008 44
Q4 2007 40
Q3 2007 44
Q2 2007 37
Q1 2007 36
Q4 2006 36
Q3 2006 36
Q2 2006 35
Q1 2006 35
Q4 2005 35
Q3 2005 35
Q2 2005 35
Q1 2005 33
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.353B $0.005B
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $45.440B 30.23
Takeda Pharmaceutical (TAK) Japan $31.638B 11.70
Grifols (GRFS) Spain $13.559B 16.43
Ionis Pharmaceuticals (IONS) United States $8.053B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.660B 10.99
Nektar Therapeutics (NKTR) United States $7.410B 10.62
Neurocrine Biosciences (NBIX) United States $7.347B 475.82
Tilray (TLRY) United States $7.176B 0.00
Sage Therapeutics (SAGE) United States $7.171B 0.00
Catalent (CTLT) United States $6.152B 25.76
United Therapeutics (UTHR) United States $5.177B 8.47
FibroGen (FGEN) United States $4.896B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.183B 22.24
Taro Pharmaceutical Industries (TARO) Israel $4.119B 13.26
USANA Health Sciences (USNA) United States $2.535B 20.69
Endo (ENDP) Ireland $2.403B 3.68
Ironwood Pharmaceuticals (IRWD) United States $2.251B 0.00
Heron Therapeutics (HRTX) United States $2.137B 0.00
Portola Pharmaceuticals (PTLA) United States $2.081B 0.00
Madrigal Pharmaceuticals (MDGL) United States $2.067B 0.00
Xencor (XNCR) United States $2.029B 0.00
Zogenix (ZGNX) United States $1.994B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.968B 24.51
Aerie Pharmaceuticals (AERI) United States $1.855B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $1.708B 0.00
PTC Therapeutics (PTCT) United States $1.707B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.642B 221.89
Theravance Biopharma (TBPH) Cayman Islands $1.491B 0.00
TherapeuticsMD (TXMD) United States $1.425B 0.00
Corcept Therapeutics (CORT) United States $1.324B 19.44
Spectrum Pharmaceuticals (SPPI) United States $1.253B 0.00
Esperion Therapeutics (ESPR) United States $1.167B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.979B 0.00
Tricida (TCDA) United States $0.964B 0.00
Radius Health (RDUS) United States $0.844B 0.00
ImmunoGen (IMGN) United States $0.824B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.587B 0.00
Siga Technologies (SIGA) United States $0.566B 0.00
Karyopharm Therapeutics (KPTI) United States $0.557B 0.00
ChemoCentryx (CCXI) United States $0.547B 43.28
Flexion Therapeutics (FLXN) United States $0.542B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.530B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.520B 30.69
GlycoMimetics (GLYC) United States $0.502B 0.00
Collegium Pharmaceutical (COLL) United States $0.500B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.493B 0.00
Forty Seven (FTSV) United States $0.468B 0.00
Odonate Therapeutics (ODT) United States $0.447B 0.00
Aptorum Group (APM) China $0.429B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.398B 0.00
Lannett Co Inc (LCI) United States $0.375B 3.49
Translate Bio (TBIO) United States $0.375B 0.00
Akebia Therapeutics (AKBA) United States $0.374B 0.00
HARPOON THERAPT (HARP) United States $0.361B 0.00
CASI Pharmaceuticals (CASI) United States $0.359B 0.00
Concert Pharmaceuticals (CNCE) United States $0.353B 0.00
KalVista Pharmaceuticals (KALV) United States $0.349B 0.00
Tyme Technologies (TYME) United States $0.329B 0.00
Dermira (DERM) United States $0.320B 0.00
Minerva Neurosciences (NERV) United States $0.303B 0.00
OptiNose (OPTN) United States $0.301B 0.00
Majesco Entertainment (PTE) United States $0.297B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.286B 10.67
Verrica Pharmaceuticals (VRCA) United States $0.285B 0.00
Aclaris Therapeutics (ACRS) United States $0.282B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.280B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.263B 0.00
Mast Therapeutics (SVRA) United States $0.239B 0.00
Opexa Therapeutics (ACER) United States $0.233B 0.00
Dova Pharmaceuticals (DOVA) United States $0.232B 0.00
IMV INC (IMV) Canada $0.220B 0.00
Affimed (AFMD) Germany $0.215B 0.00
Aratana Therapeutics (PETX) United States $0.214B 0.00
Galectin Therapeutics (GALT) United States $0.214B 0.00
Rafael Holdings (RFL) United States $0.214B 0.00
Xeris Pharmaceuticals (XERS) United States $0.209B 0.00
MEI Pharma (MEIP) United States $0.206B 0.00
Calithera Biosciences (CALA) United States $0.204B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.200B 0.00
Aldeyra Therapeutics (ALDX) United States $0.200B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.196B 0.00
ElectroCore (ECOR) United States $0.195B 0.00
Taiwan Liposome, Unsponsored ADR (TLC) Taiwan $0.191B 0.00
Recro Pharma (REPH) United States $0.186B 0.00
Redhill Biopharma (RDHL) Israel $0.177B 0.00
Molecular Templates (MTEM) United States $0.176B 0.00
AgeX Therapeutics (AGE) United States $0.172B 0.00
Zafgen (ZFGN) United States $0.168B 0.00
Nature's Sunshine Products (NATR) United States $0.165B 0.00
Aquestive Therapeutics (AQST) United States $0.164B 0.00
Ardelyx (ARDX) United States $0.162B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.158B 0.00
Ocular Therapeutix (OCUL) United States $0.153B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.152B 0.00
Adherex Technologies (FENC) United States $0.149B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.143B 0.00
Jounce Therapeutics (JNCE) United States $0.137B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.136B 0.00
Neon Therapeutics (NTGN) United States $0.131B 0.00
MediWound (MDWD) Israel $0.131B 0.00
Cardiome Pharma (CORV) Canada $0.129B 0.00
DURECT (DRRX) United States $0.127B 0.00
ProNAi Therapeutics (SRRA) Canada $0.126B 0.00
China SXT Pharmaceuticals (SXTC) China $0.120B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.119B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.117B 0.00
Champions Oncology (CSBR) United States $0.107B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.100B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.089B 0.00
Natural Alternatives (NAII) United States $0.084B 8.17
Nivalis Therapeutics (ALPN) United States $0.082B 0.00
Iterum Therapeutics (ITRM) Ireland $0.081B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.081B 0.00
Infinity Pharmaceuticals (INFI) United States $0.081B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.079B 0.00
Synergy Pharmaceuticals (SGYP) United States $0.078B 0.00
Neos Therapeutics (NEOS) United States $0.073B 0.00
Melinta Therapeutics (MLNT) United States $0.069B 0.00
Ampio Pharmaceuticals (AMPE) United States $0.067B 0.00
Immune Design (IMDZ) United States $0.067B 0.00
SCYNEXIS (SCYX) United States $0.066B 0.00
Actinium Pharmaceuticals (ATNM) United States $0.065B 0.00
Avenue Therapeutics (ATXI) United States $0.063B 0.00
Zomedica Pharmaceuticals (ZOM) United States $0.062B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.062B 0.00
Otonomy (OTIC) United States $0.061B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.061B 0.00
KemPharm (KMPH) United States $0.061B 0.00
Forward Pharma (FWP) Denmark $0.060B 0.00
CTI BioPharma (CTIC) United States $0.055B 0.00
Mannatechorporated (MTEX) United States $0.045B 0.00
Genocea Biosciences (GNCA) United States $0.045B 0.00
Achaogen (AKAO) United States $0.043B 0.00
BioLineRx (BLRX) Israel $0.043B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.042B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.040B 0.00
ContraFect (CFRX) United States $0.038B 0.00
Lipocine (LPCN) United States $0.036B 0.00
Capnia (SLNO) United States $0.036B 0.00
ProPhase Labs (PRPH) United States $0.035B 0.00
Heat Biologics (HTBX) United States $0.034B 0.00
NOVAN INC (NOVN) United States $0.031B 0.00
NanoViricides (NNVC) United States $0.030B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.027B 0.00
PharmAthene (ALT) United States $0.026B 0.00
IsoRay (ISR) United States $0.025B 0.00
ESSA Pharma (EPIX) Canada $0.023B 0.00
Biomerica (BMRA) United States $0.023B 0.00
Can-Fite Biopharma (CANF) Israel $0.023B 0.00
Citius Pharmaceuticals (CTXR) United States $0.021B 0.00
Onconova Therapeutics (ONTX) United States $0.020B 0.00
Xenetic Biosciences (XBIO) United States $0.020B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.020B 0.00
Cyanotech (CYAN) United States $0.020B 0.00
Pain Therapeutics (PTIE) United States $0.019B 0.00
Trillium Therapeutics (TRIL) Canada $0.018B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.018B 0.00
HANCOCK JAFFE (HJLI) United States $0.018B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.018B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.018B 0.00
Jaguar Animal Health (JAGX) United States $0.016B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.014B 0.00
VAXART, INC (VXRT) United States $0.014B 0.00
PRECISION THERAPEUTICS INC (AIPT) United States $0.013B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.012B 0.00
Shineco (TYHT) China $0.012B 1.32
OncoGenex Pharmaceuticals (ACHV) United States $0.012B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.010B 0.00
Regulus Therapeutics (RGLS) United States $0.009B 0.00
RXi Pharmaceuticals (PHIO) United States $0.007B 0.00
Intellipharmaceutics (IPCI) Canada $0.007B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Bio Blast Pharma (ORPN) Israel $0.005B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.004B 0.00
Midatech Pharma (MTP) United Kingdom $0.004B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.003B 0.00
Bio-Path Holdings (BPTH) United States $0.002B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00